Kairos Pharma, Ltd. will host a KOL event to discuss interim efficacy results of ENV105 in treating advanced prostate cancer patients.
The event features principal investigators from the trial providing diverse perspectives on the efficacy results.
Registration is required to participate in the webcast, emphasizing the importance of the safety and efficacy data.
Safety Results
The interim safety analysis indicated that ENV105 was well tolerated with no dose-limiting toxicities or unexpected adverse events reported.
Clinical Need
ENV105 targets CD105 to address drug resistance in hormone therapy, aiming to offer an alternative for castrate-resistant prostate cancer patients.
Key Speakers
Speakers at the KOL event include experts from prestigious institutions like Huntsman Cancer Institute and Harvard Medical School, highlighting the significance of the discussion.
- With one million men diagnosed with prostate cancer annually in the US, the demand for effective alternatives, like ENV105, is pressing.
- The development of resistance to current hormone therapies creates a need for innovative treatments like ENV105 to combat castrate-resistant prostate cancer.
Kairos Pharma's dedication to addressing drug resistance in prostate cancer through ENV105 shows promise in serving an unmet medical need for patients facing limited treatment options.